The main determinants of HIV-1 coreceptor usage are located in the V3-loop of gp120, although mutations in V2 and gp41 are also known. Incorporation of V2 is known to improve prediction algorithms; however, this has not been confirmed for gp41 mutations. Methods: Samples with V3 and gp41 genotypes and Trofile assay (Monogram Biosciences, South San Francisco, CA, USA) results were taken from the HOMER cohort (n=444) and from patients screened for the MOTIVATE studies (n=1,916; 859 with maraviroc outcome data). Correlations of mutations with tropism were assessed using Fisher's exact test and prediction models trained using support vector machines. Models were validated by cross-validation, by testing models from one dataset on the other, and by analysing virological outcome. Results: Several mutations within gp41 were highly significant for CXCR4 usage; most strikingly an insertion occurring in 7.7% of HOMER-R5 and 46.3% of HOM-ER-X4 samples (MOTIVATE 5.7% and 25.2%, respectively). Models trained on gp41 sequence alone achieved relatively high areas under the receiver-operating characteristic curve (AUCs; HOMER 0.713 and MOTIVATE 0.736) that were almost as good as V3 models (0.773 and 0.884, respectively). However, combining the two regions improved predictions only marginally (0.813 and 0.902, respectively). Similar results were found when models were trained on HOMER and validated on MOTIVATE or vice versa. The difference in median log viral load decrease at week 24 between patients with R5 and X4 virus was 1.65 (HOMER 2.45 and MOTIVATE 0.79) for V3 models, 1.59 for gp41-models (2.42 and 0.83, respectively) and 1.58 for the combined predictor (2.44 and 0.86, respectively). Conclusions: Several mutations within gp41 showed strong correlation with tropism in two independent datasets. However, incorporating gp41 mutations into prediction models is not mandatory because they do not improve substantially on models trained on V3 sequences alone.
HIV-1 infects human cells expressing the CD4 receptor and a second coreceptor on the cell surface. Although several coreceptors have been described in vitro, only the chemokine receptors CCR5 and CXCR4 have proved to be relevant in vivo [1] [2] [3] [4] [5] [6] [7] [8] [9] . In the early phase of infection, viruses using the CCR5 receptor, also known as R5 viruses, predominate. Over the course of the disease CXCR4-using variants (X4) are found in approximately 50% or more of therapy-experienced patients. The appearance of CXCR4-using variants is associated with more rapid disease progression [10] [11] [12] and reduced survival time in untreated individuals [11, 13] . It is not known, however, if their appearance is the cause or the consequence of immune exhaustion.
CXCR4-using variants can be divided into two groups: dual-tropic viruses, which can infect cells via CCR5 as well as CXCR4, and X4-tropic viruses, which can infect cells only via the CXCR4-receptor. Because most often the primary concern is to identify
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Mutations in gp41 are correlated with coreceptor tropism but do not improve prediction methods substantially
Introduction the presence of X4-using virus, both groups are often referred to as X4 viruses. A reason for this binary R5 versus X4 classification is that CXCR4-using variants are almost always found together with CCR5-using strains and rarely as a pure X4 population [12] . Furthermore, all coreceptor antagonists approved (for example, maraviroc; Pfizer [14, 15] ) or in clinical trials (vicriviroc; Schering-Plough [16] ) are CCR5-antagonists selectively blocking the CCR5-coreceptor with potency against CCR5-but not against CXCR4-using viruses. As a consequence, tropism tests are performed prior to administration of CCR5 antagonists to exclude patients harbouring CXCR4-using variants and to assure virological response.
The most widely used test to determine viral tropism is Trofile™, the Monogram Biosciences tropism assay (South San Francisco, CA, USA) [17] , a recombinant phenotypic assay using replication-defective viruses. It has been used in all CCR5 antagonists clinical trials and has therefore become the de facto gold standard for measuring coreceptor tropism. Recently, the Trofile assay has been replaced by an enhanced version. Several other phenotypic assays have been developed [18, 19] . All phenotypic approaches are usually expensive, have slow turnaround times and can only be run by a small number of labs [20, 21] . By contrast, the available genotypic approaches are faster, less expensive and yield good results on clonal data [22] . Initially substantial discordances to phenotypic assays led to the conclusion that genotypic approaches for inferring coreceptor usage were inadequate for clinical utilization [23] . However, it has recently been shown that such assays perform well when used to predict therapy response to coreceptor antagonists [24] .
Genotypic methods are mainly based on sequencing of the third hypervariable loop (V3-loop) of the envelope protein gp120 as it is commonly regarded as the main determinant of HIV-1 coreceptor usage [25] [26] [27] [28] . However, mutations in other regions of gp120 [29] [30] [31] [32] [33] [34] [35] and more recently within gp41 [36] have been demonstrated to be associated with HIV-1 coreceptor usage. Although incorporating the V2-loop is known to improve prediction methods based on V3 sequence information [37] , limited data are available for other genomic regions at present.
In this work, we analysed gp41 sequences for associations with HIV-1 coreceptor usage and possible effects on prediction algorithms on the basis of two large and well-defined HIV-1 patient cohorts containing >2,000 genotype-phenotype pairs. The aim of this study was to assess the possible additional improvement gained from including gp41 sequence variation in order to increase the reliability of genotypic prediction methods of coreceptor usage.
Methods
Datasets
Two large independent datasets were used in this study, one with drug-naive and one with drug-experienced isolates.
The British Columbia HAART Observational Medical Evaluation and Research cohort
The HOMER cohort includes all HIV-positive, antiretroviral-naive adults who started HAART though the British Columbia Drug Treatment Program between August 1996 and September 1999 (n=1,188) [38] . The baseline plasma sample from this cohort has previously been phenotyped using the prototype Trofile assay and the V3 loop sequence [23, 38] . The gp41 sequence information was available for 435 participants (369 R5 and 66 D/M or X4).
Screening samples from the maraviroc studies A4001027, A4001028 (MOTIVATE 1 and 2) and A4001029
The Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTI-VATE) 1 and MOTIVATE 2 studies were conducted to characterize the efficacy and safety of maraviroc in treatment-experienced patients [39, 40] . Patients enrolled in these studies were also screened for coreceptor usage with the original Trofile assay, and a subset with non-R5 HIV entered the A4001029 study. The entire dataset of those screened for MOTIVATE 1 and 2, including those entering A4001029 will be referred to as the MOTIVATE dataset. The gp41 region was sequenced for resistance to enfuvirtide (T-20; Fuzeon; Hoffmann-La Roche, Basel, Switzerland) and the V3-loop of the gp120 was also sequenced for tropism analyses. In total, sequence information for V3 and gp41, as well as a Trofile assay result was available for 1,915 samples (1,212 R5, 703 D/M or X4 by Trofile assay). Information on therapy outcome with maraviroc was available for the subset of this population (n=859) who entered the studies.
Sequencing
V3-loop
Using the standard operating procedures for the Nucli-SENS easyMAG (bioMérieux, Marcy l'Etoile, France), viral RNA was extracted from frozen plasma samples. Nested RT-PCR methods were used to amplify the V3 loop of gp120 from the HIV-1 env gene in triplicate from the RNA extracts. Employing the SuperScript™ III One-Step RT-PCR system with Platinum ® Taq High Fidelity enzyme (Invitrogen, Carlsbad, CA, USA), we were able to combine the reverse transcriptase (RT) and first-round PCR reactions into one step using forward primer SQV3F1 (5′ GAG CCA ATT CCC ATA CAT TAT TGT 3′) and reverse primer CO602 (5′ GCC CAT AGT GCT TCC TGC TGC TCC CAA GAA CC 3′). Second-round PCR was then performed using the Expand™ High Fidelity enzyme (Roche Diagnostics, Basel, Switzerland) with forward primer SQV3F2 (5′ TGT GCC CCA GCT GGT TTT GCG AT 3′) and reverse primer CD4R (5′ TAT AAT TCA CTT CTC CAA TTG TCC 3′). Amplicons taken from the second-round PCR reaction were sequenced in both the 5′ and 3′ directions using population-based sequencing on the ABI 3730 automated sequencer (Applied Biosystems, Foster City, CA, USA). Sequencing reaction required the use of BigDye ® Terminator (Applied Biosystems) with forward primer V3O2F (5′ AAT GTC AGY ACA GTA CAA TGT ACA C 3′) and reverse primer SQV3R1 (5′ GAA AAA TTC CCT TCC ACA ATT AAA 3′).
GP41
For gp41, viral RNA was extracted from frozen plasma sample using a Guanidine-Thiocyanate-based lysis buffer followed by precipitation using isopropanol. A single nested RT-PCR amplification was performed for each sample. The RT step was performed from the extracted RNA using Expand RT enzyme (Roche Diagnostics) and the reverse primer GP41RO (5′ CTT TTT GAC CAC TTG CCA CCC AT 3′). A first-round PCR amplification was subsequently performed using Expand™ High Fidelity enzyme and the forward primer GP41FO (5′ TTC AGA CCT GGA GGA GGA GAT AT 3′). Second-round PCR was performed using Expand™ High Fidelity enzyme with forward primer GP41Fi (5′ GGA CAA TTG GAG AAG TGA ATT AT 3′) and reverse primer GP41Ri (5′ CTG TCT TAT TCT TCT AGG TAT GT 3′). Secondround PCR amplicons were subsequently sequenced using the ABI 3700 or 3730xl automated sequencer (Applied Biosystems) using BigDye ® Terminator V3.1 (Applied Biosystems) with 11 sequencing primers, including 6 forward primers: GP41.1A (5′ CCA TTA GGA GTA GCA CCC ACC 3′), GP41.2A (5′ ATC AAG CAG CTC CAG GCA AGA 3′), SQGP41F (5′ TTT GTG GAA TTG GTT TRA CAT AA 3′), ENV8340F (5′ AAT AGA GTT AGG CAG GGA TAC TCA CC 3′), ENV8435F (5′ TGG AGA GAG AGA CAG AGA CAG ATC C 3′), ENV8522F (5′ CAG CTA CCA CCG CTT GAG AGA CTT A 3′); and 5 reverse primers: ENVR (5′ TGC CTG GAG CTG CTT GAT GCC CCA GAC 3′), GP41.1B (5′ TTG TTC ATT CTT TTC TTG CTG 3′), SQGP41R (5′ GCC TCC TAC TAT CAT TAT GAA TA 3′), SC90R (5′ GGA TCT GTC TCT GTC TCT CTC TCC A 3′), SC52R (5′ TAA GTC TCT CAA GCG GTG GTA 3′). The two second-round PCR primers also served as back-up sequencing primers.
Statistical analysis
The association of specific mutations with tropism and the covariation among pairs of mutations was assessed using Fisher's exact test. In both cases, significance was corrected for multiple testing with the Benjamini-Hochberg method at a false discovery rate of 5%. Performance of prediction methods was evaluated using receiver-operating characteristic (ROC) curves analysis in ten-fold cross validation and by testing models from one dataset against the other.
In 10-fold cross validation, the datasets were split into 10 subsets. In each cross-validation run, samples from 9 of the 10 sets were used for training of the prediction method, and the remaining subset was used for validation. When testing models from one dataset against the other, we trained the prediction method on the HOMER dataset and evaluated its performance using the MOTIVATE dataset, and vice versa. In both performance analyses the original Trofile assay result was used as gold standard. Sensitivity, specificity, and the area under the ROC curve (AUC) were used as measures.
Prediction models trained with phenotype data from both datasets were evaluated for virological outcome. The median log viral load decrease between patients with R5 and X4 virus at week 24 and the respective increase in CD4 + T-cells were used as measures. For comparison, the performance of the Trofile assay was also assessed.
All calculations were performed with the statistical programming language R [41] using the packages ROCR and covaRius [42, 43] .
Sequence alignment, encoding and coreceptor usage prediction
All sequences were multiply aligned with ClustalW [44] using standard parameters followed by manual inspection. Sequences were then encoded with a canonical indicator representation which encodes a position by a 21-bit vector. Each bit of this vector represents the presence or absence of a specific amino acid or gap at the respective position in the sequence. In case of mixtures, the bits of the respective amino acids were all set.
Viral tropism was inferred from genotype using support vector machines (SVMs). These are supervised machine learning methods often applied for classification or regression problems. A support vector machine constructs a hyperplane in a high-dimensional Euclidean space which optimally separates training data into two categories. New unseen data are then classified using this optimized hyperplane. The strength of SVMs is that they generalize very well, that is, that the risk of overtraining is minimized [45] . Previous studies for coreceptor usage prediction or prediction of resistance to antiretroviral drugs have shown that non-linear kernels do not outcompete linear kernels for simple encodings [22] , so linear kernels were employed. The cost-factor parameter c was optimized with an internal grid-search within a range from c=10 -6 to 10. The libsvm-implementation of the R-package e1071 was used to generate the prediction models.
Results
Significant mutations within gp41
Sequence mutations at each position of the V3 and gp41 domains were assessed for correlation with coreceptor usage. Table 1 shows the results of this analysis for gp41in the MOTIVATE and the HOMER datasets. Only mutations significantly associated with one or the other phenotype after correction for multiple testing in the MOTIVATE dataset are displayed (no additional mutations were statistically significant in the HOMER dataset). In general, less statistical power and fewer significant mutations in gp41 and V3 were found in HOMER than in MOTIVATE possibly due to the lower number of samples analysed and also due to the fact that the participants from MOTIVATE are heavily treatment-experienced, whereas the HOMER cohort consists of therapy-naive patients.
As can be seen in Table 1 , there are several mutations or insertions within gp41 which are highly specific for CXCR4-using virus. Of note, the 11/25 rule would have determined 5.1% of the R5 samples and 36.3% of the X4 samples in HOMER as X4 (10.4% and 60.1% in MOTIVATE). Most notably, an insertion of a hydrophobic residue after the third amino acid of HXB2-gp41 was found to be highly predictive for X4 viruses, both in the MOTIVATE and the HOMER datasets. In addition to the shown insertions of isoleucine, leucine, methionine and valine, an insertion of an alanine residue was significantly associated (P=0.0011) with X4 viruses but was less significant after correcting for multiple testing (adjusted P-value Table 1 . Mutations in gp41 significantly associated with Trofile assay result after correction for multiple testing
Mutations are relative to HXB2. The notation '3a' describes an insertion after the third position in gp41. X4-related mutations are shown bold. Note that HXB2 is an X4 virus, therefore also the residue of the wild-type residue can be predictive for X4 usage (for example, K172K In addition to this very specific insertion, other mutations previously described, such as A30T or the L34M, were found to be significant. T-20 resistance mutations were not associated with coreceptor usage. When comparing the results from the two datasets we observed a high degree of concordance in the N-terminal region of gp41 comprising the N-terminal heptad repeat 1 (HR1) but major differences at positions downstream of HR1. For example, K172K, which has also been described previously and was the second most significant mutation in the MOTIVATE dataset but failed to have any significant association in the HOMER dataset (P=0.54).
Covariance between sites in gp41 and V3
Significant gp41-mutations conferring CXCR4-using viruses were correlated against known X4 mutations within the V3 loop. Such correlation might occur due to viral fitness reasons or as a consequence of steric interference introduced by V3 mutations, which has to be resolved by other mutations within the envelope protein. We therefore performed a covariate analysis with the most significant mutations within gp41 and the 20 most significant mutations within V3 (based on results of the MOTIVATE dataset). Any mutations at the same position found to be significantly associated with X4 viruses were combined (for position 25 in HXB2, residues were also separated by net charge, note that HXB2 has two insertions and one deletion, hence position 25 in HXB2 is 24 in the consensus). Figure 1 shows the results of this analysis. The first number in each box displays the correlation, while the second number gives the logarithmic P-value of its significance. In general, there was only moderate covariance between the mutations within gp41 and V3. The strongest correlation was seen between A30T in gp41 and a negatively charged residue at position 25 (r=0.2047, position 24 in consensus) or a positively charged residue at position 26 (r=0.1975 , position 25 in consensus) of the V3 loop. There was also covariance between the highly significant insertion of a hydrophobic residue at position three in gp41 and an 11/25 mutation (r=0.1439). However, no clear pattern of correlation between mutations within gp41 and V3 was found suggesting that they are either not directly linked to each other or that there is a more global linkage pattern.
Prediction of HIV-1 coreceptor usage with gp41 mutations
To assess the effect of gp41-mutations, we incorporated them into prediction models of HIV-1 coreceptor usage. Due to the observed differences between the two datasets, we restricted our prediction models to positions up to the last position of the HR1 for which there was a high concordance between the HOMER and the MOTIVATE dataset.
In the first step we trained and tested on each dataset individually by performing a 10-fold cross validation. In addition to models trained on both V3 and gp41 sequence information, we also trained models on each of the two regions alone so that we could assess the marginal effect of the gp41 mutations.
ROC curves were generated for the respective models for the HOMER and the MOTIVATE datasets for predicting Trofile assay results (Figure 2 ). Models trained for coreceptor usage prediction on gp41 alone showed relatively high AUCs (HOMER 0.713 and MOTIVATE 0.736), confirming the association of gp41 mutations with phenotype. Surprisingly, on the HOMER-dataset, models trained solely on gp41 sequence information were almost as accurate as models trained on the V3-loop (AUC 0.773). When models were trained on data from both envelope regions, AUC increased (0.814; P<0.0001) in comparison to models using sequence information from one region alone. The respective sensitivities at the 90% specificity level (taking Trofile assay as goldstandard) were 46.9% (gp41), 54.5% (V3) and 57.5% (V3 plus gp41). More pronounced differences were found at 80% specificity where gp41 models reached 57.5%, V3 models reached 63.6% and the combined predictor reached 71.2% sensitivity for predicting X4 virus by Trofile assay. Although gp41-models also showed very good results on MOTIVATE data, they were clearly outperformed by V3 models (AUC 0.884). Their combination with V3 sequence data also did not improve prediction models substantially. Only a marginal increase in AUC to 0.902 (P=0.0002) was seen. Similar results were found when the sensitivities at 90% specificity were compared (gp41 42.8%, V3 73.3% and V3 plus gp41 73.8%).
To rule out the possibility that our prediction results do not reflect specific properties of the respective datasets, we trained models on data from one dataset and validated them on the other dataset (and vice versa; Figure 3 ). Results were comparable to those obtained by cross validation. When trained on HOMER data and validated on MOTIVATE data, prediction models using sequence information of gp41 achieved an AUC of 0.690, whereas the respective V3 models reached 0.842. The combination of the two regions only increased to an AUC of 0.859. Although sensitivity at the 90% specificity level was 37% for gp41 mutations alone, there was no significant effect when combined with V3 mutations (63.3% versus 63.6%). By contrast, models trained on MOTIVATE and validated on HOMER showed more pronounced differences. As shown in the above cross-validation, gp41-models were comparable to V3-models (AUCs 0.774 and 0.811) while the combination of the two regions improved prediction results significantly (0.881; P<0.0001). Sensitivity at 90% also increased greatly when the two regions were combined, from 51.5% (gp41) and 62.1% (V3) to 71.2% (V3 plus gp41).
Prediction results when tested for therapy outcome
Finally, we assessed whether gp41 mutations added value to the prediction of therapy outcome following the start of maraviroc-containing regimens. Predictive models were trained on all samples within the two datasets as described previously. A cutoff of 5% for the false-positive rate was used to group sequences into R5 and X4 viruses. Minor differences were seen in the numbers of predicted X4 viruses: 105 of the 852 samples were phenotyped as X4 by Trofile assay. Similar numbers were found for the V3 and the combined model (96 and 99 X4 predictions, respectively) while the gp41 model only determined 68 of the samples to be X4.
Overall, the results of the different prediction models were comparable when viral load decrease was used as the outcome measure. Figure 4A shows the median log viral load decreases of patients with predicted R5 and The corresponding values for samples determined to be R5 or X4 by Trofile assay were in the same range with 2.46 and 0.81. When analysing the increase in CD4 + T-cell counts we found differences between the models but, in contrast to our expectations, the models using the V3 loop alone outperformed models trained on sequence information of gp41 alone and in combination with V3 ( Figure 4B ). While the increase in CD4 + T-cell counts was relatively similar for samples predicted to be R5 (Trofile assay 88.5, gp41 87, V3 88.5 and V3 plus gp41 88.5), some differences were found in the samples predicted as X4 (Trofile assay 47.5, gp41 51, V3 33 and V3 plus gp41 45).
Discussion
In this analysis we have found several mutations in gp41 to be significantly associated with CCR5-or CXCR4-using viruses in two independent well-defined cohorts containing >2,000 samples, some of which have been previously reported [23] . The insertion of a hydrophobic residue after position 3 of gp41 was strongly predictive of an X4 phenotype and outperformed the 11/25 V3 loop rule on the therapy-naive dataset of the British Columbia HOMER cohort. Surprisingly we could not find any publication describing this insertion while other mutations less significant, like A30T and L34M have been previously reported.
Although these results suggest that gp41 sequence information is potentially useful for predicting HIV-1 coreceptor usage, we could not prove this consistently in our analyses. While we observed major improvements on the HOMER dataset reaching >70% sensitivity in comparison to approximately 50% from prediction based on V3 (as also previously determined in [23] ), this result was not achieved for data from the MOTIVATE screening population. The performances did not improve substantially when either sensitivity, AUC or virological outcome was used as measure. In contrast, differentiation of CD4 response was actually better for models using V3-sequence information alone for reasons that remain unclear. Further, the additional effort of sequencing the approximately 1,035 basepairs of gp41 (versus 105 bp for V3) in order to marginally improve tropism assessments should be considered.
A possible explanation for our failure to see improvements on MOTIVATE data are that our training set of HOMER samples is much smaller. One might argue + T-cell counts in patients determined to be R5 or X4 by different methods. Predictions were done with methods trained for coreceptor usage prediction with a false-positive rate of 5%. Trofile assay determined 105 of the 852 samples to be X4, while predictions based on gp41 sequences alone detected 68, V3-models 96 and models trained on both regions 99 samples to be X4.
that when using more samples for training, the performance of predictions based on V3 and gp41 would also increase significantly on MOTIVATE data. However, we believe that this would not be the case because we did not encounter substantial improvements in the cross-validation analysis on MOTIVATE where training in each fold was based on approximately 1,700 samples, either. By contrast, with regard to the study populations that differed in terms of their treatment experience, perhaps there is a difference due to previous exposure to antiretroviral drugs so that gp41 mutations are more useful in treatment-naive patients.
A limitation of our study certainly is that we have only data from 'bulk'-sequenced isolates and the original Trofile assay. This might induce a bias because of undetected minority populations, both for standard genotyping and the original phenotypic assay, which has subsequently been improved with 'ESTA'. The use of deep-sequencing, which is able to detect variants present at as low as 1% of the viral population may overcome this limitation.
Another point which could be addressed with deepsequencing methods is the analysis of the haplotype structure of the viral quasispecies. The sequences of the two regions V3 and gp41 were generated independently from each other. Thus, it is possible that a different population of viruses was sequenced for V3 than for gp41 in some samples. This would also explain why we failed to see significant covariation between mutations in V3 and gp41 despite the fact that predictions did not improve substantially when both regions were used as input. When using deep-sequencing methods, the haplotype structure of the quasispecies can be resolved so that one could better analyse linkage between mutations.
The patients enrolled in the HOMER cohort and the MOTIVATE studies carried virus primarily of subtype B [23, 40] . This might have an influence on the results. Future studies should therefore also analyse the effect of gp41 mutations in other subtypes.
Because we could not demonstrate improvements to prediction methods by integrating gp41-sequence information on the MOTIVATE dataset, we believe that sequencing this part of the envelope protein is at present not necessary when patients are screened for administration of coreceptor antagonists.
